To view this email as a web page, click here.

 
Clinical Considerations for Derm NPs and PAs
image description here In this month's Clinical Considerations for NPs and PAs, the discussions surround a step therapy approach to treating atopic dermatitis after topicals fail and the use of topical corticosteroids combined with retinoids for the irritation experienced by some acne patients.
Read my takeaways and the full stories below!
 
CLINICAL CONSIDERATIONS
 
In atopic dermatitis, are you employing the therapeutic ladder approach?
This interesting article suggests a ladder approach starting with topical agents which likely represents our practice patterns. Upon failing topical agents, this 'ladder approach' suggests systemic therapy. However, it lacks specific guidance regarding which 'systemic agents' to consider in a stepwise therapeutic approach. In your treatment of patients with atopic dermatitis, which systemic agents would you consider as first-line treatments — methotrexate, cyclosporine, or dupilumab?
In what order would you recommend these agents be used for patients who fail topicals?
ADVERTISEMENT
 
Topical corticosteroids reduce retinoid irritation, study shows
Retinoid irritation is a common condition that we discuss with acne and cosmetic patients daily. In spite of our best counseling and preventative recommendations aimed at mitigation, our patients continue to experience frustration with this condition. It may seem trivial, but because it often leads to non-compliance, we need to find effective solutions so our patients will follow through with their therapeutic regimens. This article suggests that topical corticosteroids may be effective and safe agents in the treatment of retinoid irritation.
Would you consider using a low potency topical corticosteroid agent for a short period of time upon initiating retinoid therapy if it will improve compliance?
 
JOB OPPORTUNITIES
 
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.